Bispecific antibody · Immune activation, directed at kallikrein-2 (hK2) (KLK2) and CD3 receptor complex · developed by Janssen Research & Development, LLC
Pasritamig is a humanized IgG1 bispecific antibody that binds kallikrein-2 (KLK2) on tumor cells and the CD3 receptor complex on T-cells. By cross-linking the two, it redirects T-cells to KLK2-expressing cells, causing their lysis. It is being studied in prostate cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07860255 | Phase 1 | Prostate Cancer | Not yet recruiting | JNJ |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Prostate Cancer
See JNJ's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
JNJ catalysts and pipeline →